Cowen & Co. analyst Boris Peaker maintained a Buy rating on CytomX Therapeutics Inc (CTMX) today. The company’s shares opened today at $13.13, close to its 52-week low of $12.51.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.4% and a 44.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and Pacira Pharmaceuticals.
Currently, the analyst consensus on CytomX Therapeutics Inc is a Moderate Buy with an average price target of $21.
See today’s analyst top recommended stocks >>
The company has a one-year high of $35 and a one-year low of $12.51. Currently, CytomX Therapeutics Inc has an average volume of 361.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.
